KKR to Acquire Healthium MedTech from Apax Funds

KKR Acquires Majority Stake in HealthCare Royalty Partners (HCRx)

July 30, 2025

Financial Services

KKR & Co. Inc. has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a Stamford-based biopharma royalty acquisition firm. HCRx's CEO Clarke Futch will remain as CEO with a minority interest, and the HCRx team will collaborate with KKR's healthcare platform to expand KKR's life sciences and royalty financing capabilities.

KKR Acquires Majority Stake in Healthcare Global Enterprises from CVC

February 24, 2025

Healthcare Services

KKR funds have agreed to acquire up to a 54% stake in Healthcare Global Enterprises (HCG) from CVC Asia V for a purchase price of INR 445 per share (deal value up to about US$400m). The transaction transfers majority ownership to KKR to support HCG's continued network growth, clinical and R&D expansion, and digital transformation; the deal is expected to close in Q3 2025 subject to regulatory approvals.

Petauri Health (Oak Hill) Acquires The Kinetix Group

June 13, 2023

Healthcare Services

Petauri Health, a pharmaceutical commercialization platform formed by Oak Hill Capital, has acquired The Kinetix Group (TKG), a New York–based market access, access marketing, and medical affairs agency. The Kinetix founders will remain in leadership roles as TKG becomes the inaugural add-on to the Petauri platform, expanding the platform's market access, medical affairs, and real-world evidence capabilities.

3M Acquires Acelity (and KCI) from Apax-led Consortium for $6.725B

October 11, 2019

Medical Devices

3M has completed the acquisition of Acelity and its KCI subsidiaries from funds advised by Apax Partners and consortium partners Canada Pension Plan Investment Board and the Public Sector Pension Investment Board for $6.725 billion. The transaction transfers Acelity — a global leader in advanced wound care and negative pressure wound therapy headquartered in San Antonio — to 3M, expanding 3M’s medical products capabilities.

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

KKR Acquires Majority Stake in apexanalytix from Carousel Capital

June 6, 2022

Data & Analytics

KKR has signed a definitive agreement to acquire a majority interest in apexanalytix, a supply-chain software, data and analytics provider. Carousel Capital will remain a significant minority owner; KKR’s investment is intended to accelerate apexanalytix’s global expansion, product development and talent recruitment.